Autobahn News

Autobahn Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

Autobahn Therapeutics to Present at the Stifel 2024 Virtual CNS Days

Autobahn Therapeutics to Participate in Upcoming Investor Conferences

Autobahn Therapeutics to Present at the Stifel 2023 Healthcare Conference

Autobahn Therapeutics Announces Positive Topline Results from Phase 1 Study of ABX-002, its Lead Oral Treatment for Major Depressive Disorder

Autobahn Therapeutics to Present at Upcoming Investor Conferences

Autobahn Therapeutics Completes Dosing in its Phase 1 Multiple-ascending Dose Study of ABX-002 for Major Depressive Disorder and Reports Company Progress

Autobahn Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Autobahn Therapeutics Advances ABX-002, its Lead Oral Treatment for Major Depressive Disorder, into Multi-Ascending Dose Portion of Phase 1 Trial

Autobahn Therapeutics to Present at the Stifel 2023 Virtual CNS Days

Autobahn Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ABX-002 for the Treatment for Major Depressive Disorder

Autobahn Therapeutics Announces Successful Financing to Support Strategic Advancement of ABX-002 for Treatment Resistant Depression

Autobahn Therapeutics Announces Emerging Preclinical Data Demonstrating Ability of CNS-Delivered Thyromimetics to Promote Remyelination

Autobahn Therapeutics to Present New Preclinical Data at the 2022 American Academy of Neurology Annual Meeting

Autobahn Therapeutics Announces New Preclinical Data Supporting its Novel Brain-Targeting Platform for the Development of Therapeutics for CNS Disorders

Autobahn Therapeutics Strengthens Management Team to Support Advancement of Novel Therapies for CNS Disorders

Autobahn Therapeutics Announces Orphan Drug Designation Granted to ABX-002 for the Treatment of X-linked Adrenoleukodystrophy

Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform

Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy

Autobahn Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Autobahn Therapeutics Strengthens its Team to Support its Continued Growth

Autobahn Therapeutics Completes Successful Pre-IND Meeting with FDA

Sehr gut: Autobahn roars out of stealth mode with $76M, new leitmotif in MS

ARCH-backed Autobahn launches with $76M to rebuild myelin and reverse MS

Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders